This study disclosed a progressive GLP-2 secretion impairment, gut barrier integrity disruption, and endotoxemia in response to fat as key mediators of lipotoxicity and contributors to human MASLDpresence and progression.
Dysfunctional Lipid-Induced Secretion of Glucagon-Like Peptide-2(GLP-2), but Not of Incretins Glucagon-Like Peptide-1(GLP-1)/Glucose-Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia
Musso, GiovanniCo-first
;Pinach, SilviaCo-first
;Mella, Alberto;De Michieli, Franco;Trifiro, Deborah;Cassader, Maurizio;Mariano, FilippoCo-last
;Gambino, RobertoCo-last
2026-01-01
Abstract
This study disclosed a progressive GLP-2 secretion impairment, gut barrier integrity disruption, and endotoxemia in response to fat as key mediators of lipotoxicity and contributors to human MASLDpresence and progression.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Dysfunctional Lipid-Induced Secretion of Glucagon-Like Peptide-2.pdf
Accesso aperto con embargo fino al 14/04/2027
Tipo di file:
PDF EDITORIALE
Dimensione
610.07 kB
Formato
Adobe PDF
|
610.07 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
